Out-licensing Opportunities and Partners
MDxHealth’s core business is the development and commercialization of personalized medicine products for both Clinical Diagnostics (diagnosis and prognosis tests primarily for prostate, lung, and colorectal cancers) and Pharmaco Molecular Diagnostics (predictive/companion tests for various cancer types).
Given MDxHealth’s strong patent portfolio in the field of DNA methylation and its ownership of the most widely used and cited methylation detection technology in the world (“MSP-Methylation-Specific-PCR)”, it offers the opportunity for specialized third-party companies to take a license on some of its technology components for the development of applications not pursued by MDxHealth. These applications include cancer screening tests, research market tests, and tests for non-cancer diseases where methylation plays a key role.
MDxHealth typically receives milestone payments and royalty fees from the licensees of its technology.
Existing Out-licensing and Partners Deals
Existing Licensing Opportunities
|Bladder cancer (screening and recurrence monitoring)||Several patented markers validated in both tissue and urine samples|
|Colorectal cancer (screening)||Several patented markers validated in both tissue and blood samples; several thousand samples from screening trials|
|Cervical cancer (screening/triage)||Several patented markers validated in both tissue and swab samples|
|Research market applications||Validated MSP and markers|
|Other cancers (screening)||Various markers/publications on melanoma, ovarian, lung, breast, etc.|
|Non-cancer diseases||Various publications|